TITLE

Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market

AUTHOR(S)
Kesselheim, Aaron S.
PUB. DATE
June 2013
SOURCE
PLoS Medicine;Jun2013, Vol. 10 Issue 6, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
The author discusses research on rising prescription drug costs. He references the study "Patented Drug Extension Strategies in Healthcare Spending: A Cost-Evaluation Analysis" by Nathalie Vernaz and colleagues published in the journal in 2013. He believes that addressing life-cycle management through rational regulatory oversight or alterations in patent or market exclusivity laws will be an important way that policymakers can achieve cost savings without adversely affecting public health.
ACCESSION #
88957252

 

Related Articles

  • Health care industry collaboration can keep drug coverage affordable. Gunza, Rich // New Hampshire Business Review;07/14/2000, Vol. 22 Issue 16, p9 

    Comments on the issue of rising drug costs in the United States. Health care crisis facing the country; Prescription drugs making up 12% of all national health care expenditures; Annual increases in the cost of pharmacy care for health insurers; Need for pharmaceutical companies to collaborate...

  • Don't Fall Asleep Monitoring Rx Coverage--You May Wake Up to a Nightmare. Cahn, Linda // Benefits Magazine;Dec2015, Vol. 52 Issue 12, p34 

    The article discusses the cost challenges and key contract terms that plans should address to control plan costs in the pharmaceutical industry. Topics discussed include the increases in prices of drugs, the entrance of new brand drugs, and concerns on newly approved specialty drugs. Also...

  • Taming Out-of-Control Specialty Pharmaceutical Costs. Palma, Steve // Benefits & Compensation Digest;May2010, Vol. 47 Issue 5, p1 

    The article discusses the state of the U.S. pharmaceutical industry in 2010. It states that though many drugs have been developed that have mitigated previously untreatable diseases, the costs involved are staggering. As a result, healthcare has become equally expensive for private, corporate,...

  • A healthy decision.  // BusinessToday;Aug2015, Issue 201, p1 

    The article focuses on the steps taken by the government of Oman to reduce the cost in healthcare. Topics discussed include revision and reduction in prices of drugs from five therapeutic groups, including gastrointestinal, cardiovascular, and dermatology drugs, to prevent the increase in...

  • Medicaid plans target prescription drug costs.  // Drug Store News;2/18/2002, Vol. 24 Issue 2, p1 

    Reports on the plan of Medicaid to deal with prescription drug costs in the U.S. Problems facing Medicaid; Cost effectiveness of the plan; Increase in drug prices; Implications of the plan.

  • Patients' attempts to cut medication costs.  // Pharmacy Today;Apr2015, Vol. 21 Issue 4, p13 

    Statistics are given regarding the measures taken by patients to cut their medication costs which include buying of prescription drugs from foreign countries, use of alternative therapies, and demand for cheap medication to doctors.

  • Policymakers eye increased prescription drug spending, PBM promotional activities. Wechsler, Jill // Formulary;Nov98, Vol. 33 Issue 11, p1147 

    Reports that United States policy makers are eyeing increased prescription drug spending and pharmacy benefit management promotional activities in light of the rising health care spending. Prediction for a major surge in health care spending; Congress' concern that developments are affecting...

  • Prescription drug expenditures rising -- too fast?  // CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1261 

    Comments on the rising cost of prescription drugs in Canada. Rank of Canada among developed countries with the highest annual rate of prescription drug cost; Total cost of prescription drug cost in Canada in 2004; Discussion on the reasons for the rising cost of prescription drug in the country.

  • What is the cost of administration really worth? Eder, Rob // Drug Store News;10/6/2003, Vol. 25 Issue 13, p14 

    Comments on the administrative costs of health care in the United States. Ways in which the rebate situation has made it impossible for a doctor to tell what drug is cheapest; Argument that the secretive rebate system of pharmacy benefits managers (PBM) moves more expensive drugs to the top of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics